[Federal Register Volume 61, Number 148 (Wednesday, July 31, 1996)]
[Notices]
[Pages 39986-39987]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-19443]


-----------------------------------------------------------------------


DEPARTMENT OF JUSTICE

Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.43(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on April 29, 1996, Guilford 
Pharmaceuticals, Inc., Attn: Ross S. Laderman, 6611 Tributary Street, 
Baltimore, Maryland 21224, made application to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of the 
Schedule II controlled substance cocaine (9041).
    The firm plans to manufacture methyl-3-beta-(4-
trimethylstannylphenyl)-tropane-2-carboxylate as a final intermediate 
for the production of dopascan injection.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the above application.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, D.C. 20537, Attention: DEA Federal Register Representative 
(CCR), and must be filed no later than September 30, 1996.


[[Page 39987]]


    Dated: July 25, 1996.
Gene R. Haislip,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 96-19443 Filed 7-30-96; 8:45 am]
BILLING CODE 4410-09-M